183 related articles for article (PubMed ID: 35352558)
1. Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2.
Denninger V; Xu CK; Meisl G; Morgunov AS; Fiedler S; Ilsley A; Emmenegger M; Malik AY; Piziorska MA; Schneider MM; Devenish SRA; Kosmoliaptsis V; Aguzzi A; Fiegler H; Knowles TPJ
ACS Infect Dis; 2022 Apr; 8(4):790-799. PubMed ID: 35352558
[TBL] [Abstract][Full Text] [Related]
2. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
[TBL] [Abstract][Full Text] [Related]
3. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
4. The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.
Soni MK; Migliori E; Fu J; Assal A; Chan HT; Pan J; Khatiwada P; Ciubotariu R; May MS; Pereira MR; De Giorgi V; Sykes M; Mapara MY; Muranski PJ
Front Immunol; 2023; 14():1212203. PubMed ID: 37901229
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.
Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V
J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688
[TBL] [Abstract][Full Text] [Related]
6. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection.
Abela IA; Schwarzmüller M; Ulyte A; Radtke T; Haile SR; Ammann P; Raineri A; Rueegg S; Epp S; Berger C; Böni J; Manrique A; Audigé A; Huber M; Schreiber PW; Scheier T; Fehr J; Weber J; Rusert P; Günthard HF; Kouyos RD; Puhan MA; Kriemler S; Trkola A; Pasin C
mBio; 2024 Feb; 15(2):e0272223. PubMed ID: 38270455
[TBL] [Abstract][Full Text] [Related]
7. Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel.
Ng KW; Faulkner N; Wrobel AG; Gamblin SJ; Kassiotis G
Semin Immunol; 2021 Jun; 55():101507. PubMed ID: 34716096
[TBL] [Abstract][Full Text] [Related]
8. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.
Sasson JM; Campo JJ; Carpenter RM; Young MK; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Teng AA; Pablo JV; Liang X; Yee A; Petri WA; Camerini D
mBio; 2021 Jun; 12(3):e0122921. PubMed ID: 34182775
[TBL] [Abstract][Full Text] [Related]
9. Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada.
Tanunliong G; Liu AC; Kaweski S; Irvine M; Reyes RC; Purych D; Krajden M; Morshed M; Sekirov I; Gantt S; Skowronski DM; Jassem AN
Front Immunol; 2022; 13():836449. PubMed ID: 35401521
[TBL] [Abstract][Full Text] [Related]
10. Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.
Wratil PR; Schmacke NA; Karakoc B; Dulovic A; Junker D; Becker M; Rothbauer U; Osterman A; Spaeth PM; Ruhle A; Gapp M; Schneider S; Muenchhoff M; Hellmuth JC; Scherer C; Mayerle J; Reincke M; Behr J; Kääb S; Zwissler B; von Bergwelt-Baildon M; Eberle J; Kaderali L; Schneiderhan-Marra N; Hornung V; Keppler OT
Cell Rep; 2021 Dec; 37(13):110169. PubMed ID: 34932974
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination.
Hu C; Wang Z; Ren L; Hao Y; Zhu M; Jiang H; Wang S; Li D; Shao Y
Front Cell Infect Microbiol; 2022; 12():978440. PubMed ID: 36118022
[TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of four endemic human coronaviruses and, reactivity and neutralization capability against SARS-CoV-2 among children in the Philippines.
Sayama Y; Okamoto M; Saito M; Saito-Obata M; Tamaki R; Joboco CD; Lupisan S; Oshitani H
Sci Rep; 2023 Feb; 13(1):2310. PubMed ID: 36759702
[TBL] [Abstract][Full Text] [Related]
13. Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities.
Imai K; Matsuoka M; Tabata S; Kitagawa Y; Nagura-Ikeda M; Kubota K; Fukada A; Takada T; Sato M; Noguchi S; Takeuchi S; Arakawa N; Miyoshi K; Saito Y; Maeda T
Int J Infect Dis; 2021 Oct; 111():68-75. PubMed ID: 34407480
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses.
Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP
Front Immunol; 2022; 13():1056272. PubMed ID: 36618428
[TBL] [Abstract][Full Text] [Related]
15. IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity.
Wang J; Li D; Cameron A; Zhou Q; Wiltse A; Nayak J; Pecora ND; Zand MS
J Infect Dis; 2022 Aug; 226(3):474-484. PubMed ID: 35091739
[TBL] [Abstract][Full Text] [Related]
16. Differential pre-pandemic breast milk IgA reactivity against SARS-CoV-2 and circulating human coronaviruses in Ugandan and American mothers.
Egwang TG; Owalla TJ; Okurut E; Apungia G; Fox A; De Carlo C; Powell RL
Int J Infect Dis; 2021 Nov; 112():165-172. PubMed ID: 34547496
[TBL] [Abstract][Full Text] [Related]
17. Structural mapping of antibody landscapes to human betacoronavirus spike proteins.
Bangaru S; Antanasijevic A; Kose N; Sewall LM; Jackson AM; Suryadevara N; Zhan X; Torres JL; Copps J; de la Peña AT; Crowe JE; Ward AB
Sci Adv; 2022 May; 8(18):eabn2911. PubMed ID: 35507649
[TBL] [Abstract][Full Text] [Related]
18. Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.
Fierz W; Walz B
Front Immunol; 2020; 11():1120. PubMed ID: 32582200
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa.
Tso FY; Lidenge SJ; Peña PB; Clegg AA; Ngowi JR; Mwaiselage J; Ngalamika O; Julius P; West JT; Wood C
Int J Infect Dis; 2021 Jan; 102():577-583. PubMed ID: 33176202
[TBL] [Abstract][Full Text] [Related]
20. Human seasonal coronavirus neutralization and COVID-19 severity.
Wells DA; Cantoni D; Mayora-Neto M; Genova CD; Sampson A; Ferrari M; Carnell G; Nadesalingam A; Smith P; Chan A; Raddi G; Castillo-Olivares J; Baxendale H; Temperton N; Heeney JL
J Med Virol; 2022 Oct; 94(10):4820-4829. PubMed ID: 35705514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
